New Drug Application Filed for Vandetanib in Second-Line NSCLC
AstraZeneca announced the company has submitted a New Drug Application to the FDA for an investigational drug, vandetanib ( Zactima) 100 mg, for use in combination with chemotherapy for the treatment of advanced non–small-cell lung cancer in patients previously treated with one prior anticancer therapy.
AstraZeneca announced the company has submitted a New Drug Application to the FDA for an investigational drug, vandetanib ( Zactima) 100 mg, for use in combination with chemotherapy for the treatment of advanced non–small-cell lung cancer in patients previously treated with one prior anticancer therapy.
Articles in this issue
Response to Antiangiogenesis Therapy in a Patient With Advanced Adult-Type Testicular Granulosa Cell Tumor
Testicular Granulosa Cell Tumors: Rare Tumors Need to Be Studied Too
Metabolic Therapies
Bevacizumab Approved for Metastatic Renal Cell Carcinoma
Project Zero Delay Accelerates Drug’s Path to Clinical Trial
New Drug Application Filed for Vandetanib in Second-Line NSCLC
Early-Stage BRCA2-Linked Breast Cancer Diagnosed in the First Trimester of Pregnancy Associated With a Hypercoagulable State
New Directions in the Systemic Treatment of Metastatic Thyroid Cancer
Radioiodine-Resistant Differentiated Thyroid Cancer: Hope for the Future
Thyroid Cancer Update: Dramatic Changes in the Treatment of a Rare Disease
Therapeutic Options Following Orchiectomy for Stage I Seminoma
Choosing Treatment for Stage I Seminoma: Who Should Get What?
Surveillance for Stage I Seminoma: Better the Devil You Know Than the Devil You Don’t?
Optimal Treatment in the Postorchiectomy Management of Clinical Stage I Seminoma
Related Videos
Related Content
